September 24, 2026

Alcohol use disorders may predict posttrauma-related CV risk

Among trauma-exposed adults, alcohol use disorders ranked above PTSD, depression, and other psychiatric diagnoses as predictors of major cardiac and cerebrovascular events.

MDSpire News

September 22, 2026

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.

MDSpire News

September 18, 2026

Migraine therapy in congenital heart disease

COMPETE directly compared 3 antithrombotic strategies with an established preventive treatment in a randomized clinical trial.

MDSpire News

September 14, 2026

Menopause may be underdocumented in EHRs

Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.

MDSpire News

September 08, 2026

Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.

MDSpire News

September 08, 2026

CKM staging faces an early vascular test

Investigators examined Life’s Essential 8 scores and carotid ultrasonography measures across cardiovascular-kidney-metabolic stages in 1,283 young adults.

MDSpire News

September 02, 2026

Medical Oddities: Dogs share our mortality markers

The bond with dogs runs deeper, the brain enjoys a good sweat, love on screen gets real, and tea carries a little more weight.

MDSpire News

August 31, 2026

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

MDSpire News

August 28, 2026

FDA expands tirzepatide indication to cardiovascular risk reduction

SURPASS-CVOT compared tirzepatide head-to-head with dulaglutide in 13,299 participants.

MDSpire News

August 28, 2026

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

MDSpire News